These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10481831)

  • 1. Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin.
    Abelson JL; Liberzon I
    Neuropsychopharmacology; 1999 Oct; 21(4):485-94. PubMed ID: 10481831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose response of arginine vasopressin to the CCK-B agonist pentagastrin.
    Abelson JL; Le Mellédo J; Bichet DG
    Neuropsychopharmacology; 2001 Feb; 24(2):161-9. PubMed ID: 11120398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of repeat exposure on neuroendocrine and symptom responses to pentagastrin.
    Khan S; Liberzon I; Abelson JL
    Psychiatry Res; 2004 May; 126(3):189-95. PubMed ID: 15157745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects.
    Abelson JL; Liberzon I; Young EA; Khan S
    Arch Gen Psychiatry; 2005 Jun; 62(6):668-75. PubMed ID: 15939844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothalamic-pituitary adrenal response to cholecystokinin-B receptor agonism is resistant to cortisol feedback inhibition.
    Abelson JL; Young EA
    Psychoneuroendocrinology; 2003 Feb; 28(2):169-80. PubMed ID: 12510010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of propranolol on symptom and endocrine responses to pentagastrin.
    Khan S; Liberzon I; Abelson JL
    Psychoneuroendocrinology; 2004 Oct; 29(9):1163-71. PubMed ID: 15219640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels.
    Radu D; Ahlin A; Svanborg P; Lindefors N
    Psychopharmacology (Berl); 2002 Jun; 161(4):396-403. PubMed ID: 12073167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
    McCann UD; Slate SO; Geraci M; Uhde TW
    Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of central administration of the CCK-B receptor agonist pentagastrin on feeding and cortisol release in sheep.
    Ebenezer IS; Parrott RF
    Methods Find Exp Clin Pharmacol; 1996 May; 18(4):235-8. PubMed ID: 8803955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology.
    Abelson JL; Nesse RM; Vinik AI
    Biol Psychiatry; 1994 Jul; 36(2):84-96. PubMed ID: 7524696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
    Demiralay C; Jahn H; Kellner M; Yassouridis A; Wiedemann K
    World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of time of preparation on pentagastrin-induced symptom, endocrine and cardiovascular responses.
    Khan S; Briggs H; Abelson JL
    Psychiatry Res; 2008 Mar; 158(2):141-6. PubMed ID: 18222546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between respiratory, endocrine, and cognitive-emotional factors in response to a pharmacological panicogen.
    Lyubkin M; Giardino ND; Abelson JL
    Depress Anxiety; 2010 Nov; 27(11):1011-6. PubMed ID: 20721903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentagastrin test for anxiety--psychophysiology and personality.
    Radu D; Ahlin A; Svanborg P; Lindefors N
    Psychopharmacology (Berl); 2003 Mar; 166(2):139-45. PubMed ID: 12529809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPA axis activity in patients with panic disorder: review and synthesis of four studies.
    Abelson JL; Khan S; Liberzon I; Young EA
    Depress Anxiety; 2007; 24(1):66-76. PubMed ID: 16845643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
    Demiralay C; Agorastos A; Yassouridis A; Jahn H; Wiedemann K; Kellner M
    Psychoneuroendocrinology; 2017 Feb; 76():14-18. PubMed ID: 27871026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin and panic disorder: past and future clinical research strategies.
    Bradwejn J; Koszycki D
    Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
    Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
    Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of perceived control and cognitive coping on endocrine stress responses to pharmacological activation.
    Abelson JL; Khan S; Liberzon I; Erickson TM; Young EA
    Biol Psychiatry; 2008 Oct; 64(8):701-707. PubMed ID: 18571624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260.
    Lines C; Challenor J; Traub M
    Br J Clin Pharmacol; 1995 Mar; 39(3):235-42. PubMed ID: 7619662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.